Twist Bioscience (NASDAQ:TWST) Shares Down 7.4% on Analyst Downgrade

by · The Cerbat Gem

Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report)’s share price dropped 7.4% during mid-day trading on Tuesday after Barclays lowered their price target on the stock from $40.00 to $37.00. Barclays currently has an overweight rating on the stock. Twist Bioscience traded as low as $24.62 and last traded at $24.4950. Approximately 412,734 shares changed hands during trading, a decline of 69% from the average daily volume of 1,338,343 shares. The stock had previously closed at $26.46.

A number of other analysts also recently weighed in on the company. Evercore ISI decreased their price target on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Twist Bioscience in a report on Thursday. Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 4th. Finally, Stephens initiated coverage on shares of Twist Bioscience in a research note on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price objective on the stock. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $47.50.

Read Our Latest Analysis on TWST

Insider Buying and Selling at Twist Bioscience

In related news, CFO Adam Laponis sold 5,517 shares of the company’s stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $31.44, for a total transaction of $173,454.48. Following the transaction, the chief financial officer owned 111,008 shares of the company’s stock, valued at approximately $3,490,091.52. This represents a 4.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Dennis Cho sold 1,019 shares of Twist Bioscience stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $32.08, for a total transaction of $32,689.52. Following the completion of the sale, the insider directly owned 120,694 shares of the company’s stock, valued at $3,871,863.52. The trade was a 0.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 122,865 shares of company stock valued at $3,879,926. Corporate insiders own 3.01% of the company’s stock.

Institutional Trading of Twist Bioscience

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Twist Bioscience by 37.3% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 497,138 shares of the company’s stock worth $13,989,000 after acquiring an additional 134,929 shares during the period. CANADA LIFE ASSURANCE Co raised its stake in Twist Bioscience by 3.4% during the third quarter. CANADA LIFE ASSURANCE Co now owns 20,485 shares of the company’s stock worth $553,000 after purchasing an additional 675 shares during the period. Verition Fund Management LLC acquired a new position in shares of Twist Bioscience in the 3rd quarter valued at $363,000. Sherbrooke Park Advisers LLC acquired a new position in shares of Twist Bioscience in the 3rd quarter valued at $242,000. Finally, Quarry LP purchased a new stake in shares of Twist Bioscience during the 3rd quarter valued at $28,000.

Twist Bioscience Trading Down 5.3%

The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. The firm has a market capitalization of $1.51 billion, a price-to-earnings ratio of -19.11 and a beta of 2.43. The business has a fifty day moving average price of $29.74 and a 200 day moving average price of $31.21.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last issued its earnings results on Friday, November 14th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.05). The firm had revenue of $99.01 million during the quarter, compared to analyst estimates of $97.40 million. Twist Bioscience had a negative net margin of 20.63% and a negative return on equity of 27.62%. Twist Bioscience has set its Q1 2026 guidance at EPS. FY 2026 guidance at EPS. As a group, equities analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Twist Bioscience Company Profile

(Get Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Featured Articles